11 Best Feminist Stocks To Invest In

Page 3 of 10

8. Zoetis Inc. (NYSE:ZTS)

Number of Hedge Fund Shareholders In Q1 2024: 65

CEO: Kristin C. Peck

Zoetis Inc. (NYSE:ZTS) is a diversified animal healthcare company that provides medicines, diagnostic equipment, and other products. While its earnings performance has been mixed lately as Zoetis Inc. (NYSE:ZTS) has beaten adjusted analyst EPS estimates in just two of its four latest quarters, the average of 14 one year analyst share ratings is Strong Buy and the average share price target is $212.29. The latest earnings report released in May 2024 was a solid set of results. It saw Zoetis Inc. (NYSE:ZTS)  beat adjusted EPS estimates of $1.35 and revenue estimates of $2.15 billion by posting $1.35 and $2.2 billion in the segments respectively. As a result, the shares soared by more than 4% after the earnings report.

Owing to its business model of being one of few pure play animal health companies on Wall Street enables Zoetis Inc. (NYSE:ZTS)’s forward P/E ratio of 29.76 to exceed the S&P’s 21. This implies that investors expect the shares to outpace the broader market in growth terms. Baron Funds mentioned Zoetis Inc. (NYSE:ZTS) in its Q1 2024 investor letter and shared:

Zoetis Inc. is a global leader in medicines and vaccines for companion and farm animals, operating in more than 120 countries across eight core species and five major product categories. Shares fell after the company reported mixed fourth quarter results that fell short of high market expectations and issued below-consensus 2024 guidance. While revenue beat Street forecasts primarily on higher sales in the livestock category, EPS missed consensus due to FX headwinds, costs associated with an acquired asset, and investments related to the U.S. launch of canine arthritis drug Librela. Investor concerns about new parasiticide competition and inefficiencies with the Librela ramp also weighed on the share price. Zoetis remains an attractive holding given its consistent above-market growth, diverse portfolio and rich pipeline, new and innovative product flow, and attractive end-markets that have proven resilient in periods of heightened economic uncertainty.

Page 3 of 10